Product logins

Find logins to all Clarivate products below.


Acute Coronary Syndrome – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of acute coronary syndrome (ACS) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report both the diagnosed incidence and prevalence of ACS in each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s ACS forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of ACS?
  • How will improvements in survival change the number of people living with a diagnosis of ACS?
  • Of all people diagnosed with ACS, how many in each country are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACS over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 24 ACS patient populations, as follows:

  • Diagnosed events of ACS.
  • Diagnosed events of ACS by subtype (STEMI / NSTEMI / UA).
  • Diagnosed events of ACS by drug-treatment status.
  • 12-month diagnosed prevalent cases of ACS.
  • 12-month diagnosed prevalent cases of ACS by subtype (STEMI / NSTEMI / UA).
  • Diagnosed lifetime prevalent cases of ACS.
  • Diagnosed events of ACS with a history of myocardial infarction (MI).
  • Diagnosed events of ACS with a history of stroke.
  • Diagnosed events of ACS with hypertension.
  • Diagnosed events of ACS with hyperlipidemia.
  • Diagnosed events of ACS with diabetes mellitus.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Ulcerative Colitis – Epidemiology – Epidemiology – Ulcerative Colitis – Mature Markets
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…
Report
Eosinophilic Esophagitis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…
Report
Gout – Epidemiology – Americas
Clarivate Epidemiology’s coverage of gout comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of gout for each country, as well as…